AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
AtaiBeckley is in structured discussions with pharma companies and royalty investors about a potential partnership for its lead candidate, intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression (TRD), sources close to the company told Psychedelic Alpha. Here, we take a closer look...
External link. We are not responsible for the content.
Read more βMore From Psychedelic Alpha
PΞ±+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published
Policy Round-Up: State Momentum, Congressional Signals, and Coloradoβs Data Build-Out β’ RAND Survey: Americans Divi...
PΞ±+ February 2026 Psychedelic Bill Roundup
A state-by-state and federal review of psychedelics-related bills introduced or advanced in February 2026, including ...
The State of the Psychedelic Industry & Open Questions (Video)
In the third video of a three-part series, Psychedelic Alphaβs Josh Hardman takes a look at some broader open questio...
Latest News
Psychedelics Are Booming, But Who Is Getting Left Out?
This fast-moving renaissance is leaving out key voices, even as many within the psychedelic culture are pushing to br...
Party, Party Party!
Official After Party, plus more talks announced!
To What Extent Are Memories of Psychedelic Trips Embellished?
Memory distortion β including embellishment and false memories β is a natural human tendency that applies to psychede...
Protected: RELOCATING THE ROOT
There is no excerpt because this is a protected post.
What do police think about psychedelic therapy? 5 Questions for psychologist Alexandra Hopkins
Hopkins discusses her work on the perspectives of military and law enforcement.
Martha Hammel and Tasia Poinsatte β Aspen Psychedelic Symposium
Aspen Psychedelic Symposium is the focus of this conversation with Martha Hammel of the Aspen Psychedelic Resource Ce...